A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis
Status:
Completed
Trial end date:
2020-03-18
Target enrollment:
Participant gender:
Summary
This is a Phase 3, multi-center, prospective, randomized, placebo-controlled, delayed
treatment, double-blind, study to evaluate the effectiveness, and safety of a single, oral
dose of Solosec® containing 2 grams of secnidazole in female patients with trichomoniasis.